Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

PC-DAC:Exendin-4 safe, with positive efficacy on glucose reduction in diabetics

Sep. 18, 2006

Transition Therapeutics and JDRF partner on GLP1-I.N.T.

Sep. 18, 2006

ADA/EASD consensus recommends metformin at diagnosis of type 2 diabetes

Sep. 15, 2006

Radius and Karo Bio announce licensing agreement for novel SARMs

Sep. 15, 2006

Component of brown seaweed shows antiobesity properties

Sep. 15, 2006

Good oral bioavailability and safety profile for new oxytocin antagonist

Sep. 15, 2006

Recent patents describe new agents for endocrine-related disorders

Sep. 15, 2006

Arena presents novel GPR119 agonist for the treatment of non-insulin dependent diabetes

Sep. 14, 2006

Positive preclinical results for Abbott's novel DPP-IV inhibitor

Sep. 14, 2006

Recent patents report novel therapeutic agents for lipoprotein disorders and obesity

Sep. 14, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...